JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kramer, P. R.
Right arrow Articles by Sinden, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kramer, P. R.
Right arrow Articles by Sinden, R. R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 40, 28590-28597, October 1, 1999


Transcriptional State of the Mouse Mammary Tumor Virus Promoter Can Affect Topological Domain Size in Vivo*

Phillip R. KramerDagger §, Gilbert Fragoso, William Pennieparallel , Han Htun**, Gordon L. Hager, and Richard R. SindenDagger Dagger Dagger

From the Dagger  Institute of Biosciences and Technology, Center for Genome Research, Texas A&M University System Health Sciences Center, Houston, Texas 77030-3303 and  Laboratory of Receptor Biology and Gene Expression, NCI, National Institutes of Health, Bethesda, Maryland 20896-5055

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Unrestrained DNA supercoiling and the number of topological domains were measured within a 1.8 megabase pair chromosomal region consisting of about 200 tandem repeats of a mouse mammary tumor virus promoter-driven ha-v-ras gene. When uninduced, unrestrained negative supercoiling was organized into 32-kilobase pair (kb) topological domains. Upon induction, DNA supercoiling throughout the region was completely relaxed. Supercoiling was detected, however, when elongation was blocked before or following induction. The formation of transcription initiation complexes upon addition of dexamethasone decreased the domain size to 16 kb. During transcription the domain size was 9 kb, the length of one repeat. These results suggest that topological domain boundaries can be "functional" in nature, being established by the formation of activated and elongating transcription complexes.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Topological domains, often referred to as chromosomal loops, have been detected in many organisms including Escherichia coli (1), Drosophila (2), and humans (3) (for review see Ref. 4). The formation of a topological domain requires restraint of the DNA helix such that rotation of one strand of the DNA double helix around the other is prevented. Consequently, DNA within a topological domain can contain a linking number deficit that is manifest as unrestrained superhelical energy (for review see Ref. 5). Domain boundaries may result from the attachment of the DNA at specialized sites (i.e. MARs1 or SARs) (6, 7) onto the nuclear matrix. Recently a bipartite sequence element has been identified within matrix attachment regions that may be important in chromosome organization or function via these sites (8). Alternatively, topological domain boundaries may be functional in nature resulting from the attachment of functional proteins such as RNA or DNA polymerase complexes to the nuclear membrane (9). For example, in Salmonella typhimurium membrane attachment of TetA leads to the formation of a topological domain boundary defined by the transcriptional complex where the RNA is being translated (10). In addition, in yeast, telomeric sequences can act as functional anchor points for chromosome organization to provide blocks to the transmission of supercoils across the block (11). Other DNA·enzyme complexes in bacteria, such as that created by UvrAB can also act as a boundary to supercoiling (12).

DNA in living bacterial cells is organized with a linking number deficit leading to a state of unrestrained negative supercoiling (1, 13). Although, DNA is negatively supercoiled in bacterial cells, not all supercoiling is unrestrained. About half the supercoils in DNA in Escherichia coli are restrained, possibly by the wrapping of DNA around histone-like proteins (14-18). Consequently, in vivo measurements of levels of supercoiling are about half that measured for the purified chromosome (19-22). Initial studies of supercoiling in eukaryotic cells failed to detect unrestrained supercoiling averaged over the entire chromosome (13), presumably due to the restraint of supercoils through the organization of DNA into nucleosomes. However, analyses of individual genes in Drosophila, mouse, and human cells have revealed the presence of unrestrained supercoiling associated with gene regions (2, 23-26), whereas DNA outside the functional hsp70 domain at locus 87A Drosophila was completely relaxed (2). However, a relationship between transcription or transcriptional activation and unrestrained supercoiling remains to be clearly established. For example, the level of supercoiling within a transcriptionally active hygromycin resistance gene introduced into different regions of the human genome can vary from highly supercoiled to relaxed (26).

The mouse mammary tumor virus promoter provides a model system in which the nucleosomal organization and nucleosomal reorganization upon transcription activation are extremely well characterized (27). Transcription rapidly follows the addition of the glucocorticoid hormone dexamethasone, allowing analysis of the chromatin under conditions of gene repression or activation. When stably introduced into the genome, the mouse mammary tumor virus (MMTV) promoter acquires six positioned nucleosome families (28), positioned over the binding sites for the glucocorticoid receptor and associated factors involved in promoter activation. Steroid hormone induction of the MMTV promoter with dexamethasone renders the DNA sequences associated with the B nucleosome family accessible to restriction endonuclease digestion (28). The hormone-dependent increased nucleosome accessibility is believed to be mechanistically responsible for the loading of transcription factors and the subsequent induction of transcriptional activation (29, 30). The increase in enzyme accessibility of nucleosome B in a stably integrated MMTV promoter is 15-20% in one mouse cell line, suggesting that transcriptional activation of the promoter occurs at similar levels (31).

The well characterized MMTV promoter and the availability of a cell line containing multiple tandem copies of this promoter afford an excellent system in which to study the effects of gene activation and transcriptional elongation on the level of DNA supercoiling and the number of topological domains. We have studied the change in supercoiling and topological domain size in a DNA region containing approximately 200 copies of the MMTV promoter 5' of the ha-v-ras gene to understand the role of chromatin organization and supercoiling on gene expression. The transcriptional state of the gene influences the topological domain size and the level of unrestrained supercoiling. The average domain size within the tandem array of MMTV promoter-driven genes changes upon transcriptional activation and elongation suggesting that transcription complexes are functional topological domain boundaries.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cells, Cell Growth, and DNA Purification-- Cell line 3134 contains approximately 200 copies of the 9-kb fragment (pM18D) of the plasmid pM18 (28) in a tandem array in a single chromosomal location. Cells were maintained as a monolayer in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum at 37 °C in a 5% CO2 atmosphere. To incorporate BrdUrd into the DNA, cells were grown in Dulbecco's modified Eagle's medium + 10% fetal bovine serum containing 10 mM bromo-2-deoxyuridine. At this concentration, 45% of the thymidines were substituted with bromo-2-deoxyuridine in hamster cells (32). 24 h before use, cells were incubated in Dulbecco's modified Eagle's medium lacking phenol red and containing 10% charcoal-stripped serum (Hyclone). For transcriptional activation, cells were treated with dexamethasone at a concentration of 0.5 µM for 1 h, either before or after a 60-min treatment with 50 µg/ml of alpha -amanitin (Roche Molecular Biochemicals).

Genomic DNA Analysis-- Genomic DNA from approximately 1.2 × 106 3134 cells, lysed in agarose blocks, was digested overnight at 37 °C with various restriction enzymes. For clamped homogeneous electric field (CHEF) gel analysis, the digested DNAs were separated for 83 h in a 0.8% agarose gel equilibrated with 1X TAE buffer (0.04 M Tris base, 0.04 M glacial acetic acid, 0.001 M EDTA) in a Bio-Rad CHEF Mapper XA pulsed field electrophoresis system with the auto algorithm supplied by the manufacturer for optimal separation of 1 to 3 mega base pair DNAs. Following electrophoresis, location of the Hansenula wingei chromosomal marker was determined by ethidium bromide staining. Genomic DNA was transferred to a nylon membrane (Amersham Hybond-N+) by capillary action under alkali conditions. This blot was hybridized for 48 h under moderate stringency (2× SSC (0.3 M NaCl, 0.03 M sodium citrate, pH 7.0); 5× Denhardt's solution (0.1% Ficoll (Mr 400,000), 0.1% polyvinyl pyrrolidone (Mr 400,000), and 0.1% bovine serum albumin); 50% deionized formamide; 1% SDS; 100 µg/ml denatured sheared salmon sperm; 55 °C) with a radioactive RNA probe derived from the 69% transforming portion of bovine papilloma virus (BPV; sense strand position 1234-3224 of BPV-1 DNA (GenBankTM accession number X02346)). The blot was washed at 42 °C in 0.2× SSC, 0.1% SDS following treatment with RNase A (25 µg/ml) and RNase T1 (10 µg/ml) at room temperature in 2× SSC. Subsequently, the blot was placed on a PhosphorImager plate to collect the radioactive signal. For field inversion gel electrophoresis, the genomic DNAs digested in plugs as described above were separated in a 1% agarose gel in 0.5× TBE buffer (0.045 M Tris base, 0.045 M boric acid, 0.001 M EDTA) using the auto algorithm feature optimal for separation of 2- to 50-kilobase pair DNA. Reference marker DNA in this case was HindIII-digested lambda DNA (range of fragments, 8.3 to 48.5 kb). The separated genomic DNA was analyzed by hybridizing to the BPV RNA probe.

S1 Analysis-- The S1 analyses were performed as described previously (33). Briefly, total cellular RNA was extracted by phenol-chloroform, precipitated with ethanol, and dissolved in H2O. Single-stranded MMTV probes were synthesized by primer extension in the presence of [alpha -32P]ATP, using an oligonucleotide priming from +85 in the long terminal repeat (LTR) (5'-TCTGGAAAGTGAAGGATAAGTGACGA), and SacI-cut pM18 as a template (end point at -105) (34). The probes were purified by electrophoresis in denaturing gels, recovered by the "crush-and-soak" method, and 105 cpm were hybridized to 10 µg of RNA in 80% formamide, 0.2 M NaCl, 1 mM EDTA, 40 mM PIPES, pH 6.4, for 6-12 h at 37 °C. Hybrids were treated with 100 units of S1 nuclease for 1 h at room temperature, in 50 mM NaCl, 1 mM zinc acetate, 30 mM sodium acetate, pH 4.6, and then extracted with phenol-chloroform and precipitated with ethanol. Digestion products were resolved in denaturing 8% acrylamide sequencing gels. Visualization of the separated fragment was achieved with a PhosphorImager, and quantitation performed with the ImageQuant program (Molecular Dynamics).

Isolation and Restriction of Nuclei-- Preparation of nuclei, restriction enzyme treatment, and analysis by primer extension was performed as described previously (31). Briefly, treated or untreated cells were scraped into cold phosphate-buffered saline and homogenized with a dounce ("A" pestle) in 0.3 M sucrose, 3 mM CaCl2, 2 mM magnesium acetate, 10 mM HEPES, pH 7.8, 0.5 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 1% Triton X-100. The homogenate was diluted 1:1 with digestion buffer (25% glycerol, 5 mM magnesium acetate, 10 mM HEPES, pH 7.8, 0.5 mM dithiothreitol, 0.1 mM EDTA), and centrifuged through a pad containing dilution buffer for 15 min at 1,000 × g and 4 °C. Nuclear pellets were resuspended in 25% glycerol, 5 mM HEPES, pH 7.8, 0.1 mM EDTA, 0.5 mM dithiothreitol. 10 µg of DNA equivalents of nuclei was restricted with 100 units of SacI, for 15 min at 37 °C in 50 mM NaCl, 50 mM Tris-Cl, pH 8, 0.5 mM MgCl2, 1 mM beta -mercaptoethanol (35) extracted with phenol-chloroform, and precipitated with ethanol. The extracted DNA was cut to completion with DpnII before primer extension to determine the fractional cleavage. To obtain a linear amplification of the signal, primer extensions with Taq polymerase were thermally cycled in 50 mM KCl, 50 mM Tris-Cl, pH 8.8, 200 µM dNTP, 3.5 mM MgCl2, 0.1% Triton X-100, using an oligonucleotide priming from +27 in the LTR (5'-ACAAGAGGTGAATGTTAGGACTGTTGC). Extension products were extracted with phenol-chloroform and precipitated with ethanol before electrophoresis in sequencing gels and analysis in the PhosphorImager.

Nicking, Psoralen Cross-linking, and Southern Protocols-- Following growth in the presence of bromo-2-deoxyuridine, the DNA nicking was accomplished by exposure of the cells to 313-nm light using a mercury vapor lamp with a K2CrO4/NaOH filter as described previously (26, 36-39). Subsequent treatment with psoralen and 360-nm light, and DNA purification protocols were described previously (26).

For Southern analysis, 7 µg of chromosomal DNA were digested to completion at 37 °C with 100 units of SpeI in 60 µl of restriction buffer. After digestion, DNA was purified and treated with glyoxal aldehyde and dimethyl sulfoxide (Me2SO) as described previously (26). DNA samples were separated on a 1% agarose gel in 10 mM sodium phosphate (pH 7.0) as described (40), the gel was denatured, and the DNA was transferred to a nylon membrane (26). For hybridization analysis of the MMTV promoter, a 3.0-kb SpeI fragment was isolated from plasmid pM18 (28) and labeled with [alpha -32P]CTP using the random priming method (Roche Molecular Biochemicals). The membrane was hybridized at 65 °C for 12 h, washed twice with 2× SSC (300 mM NaCl, 30 mM sodium citrate, pH 7.0) containing 0.1% SDS at 65 °C for 60 min. Quantitation was completed using a Molecular Dynamics PhosphorImager using ImageQuant software. The fraction of DNA cross-linked (Fx) was calculated by dividing the area of the cross-linked peak by the sum of the area for the cross-linked and noncross-linked peaks. The cross-links per kilobase (Xl/kb) were calculated using the formula Xl/kb = -ln(1- Fx)/S, as described (24), where S is the size of the restriction fragment (S = 3.0 kb for the SpeI fragment of pM18). RI/N values represent an average of two Southern blots each from a minimum of three separate experiments. The ratio of the mean cross-linking rate in intact verses relaxed domains (RI/N = Xl/kbI/Xl/kbN) reflects the level of unrestrained supercoiling (24). An unpaired, two-tailed, t test was performed with these RI/N values, and a significant difference is indicated if p <=  0.05.

Measurement of Single Strand Breaks-- The frequency of single strand breaks introduced by BrdUrd photolysis was determined as described previously (26) with the following modifications: 5 ml of 5-20% alkaline sucrose gradients were centrifuged at 35,000 rpm in a Beckman SW55Ti rotor for 4 h. Thirty equal volume fractions were collected from the bottom of the tube onto 3-cm square sections of a nylon membrane. After baking at 80 °C for 2 h, the membrane was hybridized with the 3.0-kb SpeI fragment 32P-labeled probe of pM18D containing the MMTV promoter and v-ras gene (Fig. 1). The membrane was washed twice with 2× SSC at 65 °C for 60 min. The membrane was dried then the 3-cm sections were placed into vials with scintillation fluid and counted for radioactivity. Molecular weights of the single strand DNA fragments (Z) were calculated (41), and the number of single strand breaks per tandem array was calculated using a molecular weight of 338 g/mol bp and 8 × 106 bp per tandem array.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Characterization of Cell Line 3134-- Cell line 904.13 was originally established by transformation of C127 cells with a bovine papilloma virus vector containing the MMTV promoter driving expression of the ha-v-ras gene (Fig. 1C). Cell line 3134 was derived from the 904.13 line after a spontaneous event resulted in the integration and amplification of the episome. CHEF gel analysis (Fig. 1A) of DNA from this cell line with three different restriction enzymes, which do not cut the circular DNA construct, resulted in fragments ranging in size from 1.8 to 2.2 × 106 base pairs. Partial digestion with a single-cut enzyme produced a ladder of fragments with a repeat size of 9 kb (Fig. 1B). These data indicate that the cell contains a large tandem array with approximately 200 head to tail copies of the original 9-kb fragment (Fig. 1C). Details of the 9-kb repeat unit are diagrammed in Fig. 1D.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 1.   Genomic DNA analysis of cell line 3134. Plasmid pM18, containing both the MMTV LTR driving ha-v-ras and the 69% transforming fragment of the BPV, was used to transform C127 mouse mammary cells to produce the 904.13 cell line with a replicating BPV-MMTV episome (28). The reporter sequence also includes viral-like 30 S sequences upstream and downstream of ras (28). The 3134 cell line was derived from 904.13 and resulted from spontaneous integration and amplification of the episome in the genome. A, CHEF gel analysis. Agarose plugs of 3134 genomic DNA, digested with restriction enzymes EcoRV (lane 1), NdeI (lane 2), EcoRV and NdeI (lane 3), and NotI (lane 4) along with H. wingei chromosomal markers, were separated in a 0.8% agarose gel by CHEF electrophoresis. Following electrophoresis, the location of the H. wingei DNA were noted, and the separated genomic fragments transferred to a nylon membrane and probed with radioactive BPV sequences. Location of the H. wingei chromosomal marker is indicated on the left, whereas the adjacent panel shows a plot of the distance migrated versus the size of the marker DNAs. B, field inversion gel electrophoresis gel analysis. The same as in panel A except 3134 genomic DNA in agarose plugs were undigested (lane 2), fully digested with BamHI (lane 3) and EcoRI (lane 5), or partially with BglII (lane 4), and separated on a 1% agarose gel by FIGE to separate fragments in the 2-50 kilobase pair range optimally. Marker DNA are HindIII fragments (lane 1), and a range of fragments from 8.3- to 48.5-kb of lambda DNA (not shown). Size of the genomic DNA fragments hybridized to the probe is indicated on the right in kilobase pairs. C, genomic organization of BPV-MMTV-ras in the 3134 cell line. The data in panels A and B indicate that this cell line carries 200 copies of the integrated construct in a tandem array. D, details of the repeat unit. The low resolution positions of nucleosome families in the LTR are illustrated by multiple brackets (28). The sites recognized by SpeI in the BPV backbone and the ras gene, as well as the DpnII and SacI sites in the nucleosome B region, are indicated by arrows.

A 3,026-bp SpeI fragment encompassing the MMTV promoter was used to assess the level of unrestrained supercoiling within the inserts of the tandem array (Fig. 1D). This fragment contains the entire MMTV LTR, and most of the transcribed region of the ras sequence. The percentage of MMTV templates activated by dexamethasone in this cell line was assessed by hypersensitivity to SacI cleavage, which cuts in the nucleosome B region of the promoter (Fig. 1D) (29, 31, 42). In a representative experiment, about 7-8% of the SacI sites were accessible in control cells or in cells treated with alpha -amanitin (Fig. 2; Control and Amanitin). Treatment with dexamethasone resulted in an increase in the accessibility of this region, approximately 23% of the promoters were cut (Fig. 2; Dex). This represents an increase of 0.15-0.16 in the fractional cleavage, in agreement with previous studies (31, 42) and suggesting that 15-20% of the promoters are active at the time of the assay. In addition, treatment with dexamethasone following a 1-h pretreatment of the cells with alpha -amanitin resulted in a similar increase in fractional cleavage (Fig. 2; Dex + Amanitin), indicating that remodeling of the Nuc-B region occurs independently of transcription, as suggested by others (43).


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 2.   Steroid-dependent hypersensitivity of the MMTV promoter is refractory to alpha -amanitin treatment. Nuclei were prepared from treated or untreated 3134 cells, digested with SacI, and the extracted DNA cut to completion with DpnII. Analysis of the cleavage by primer extension was conducted with an oligonucleotide priming from +27 in Nucleosome A toward the Nucleosome B region. The chart shows the fractional cleavage by SacI in cells treated as follows: untreated (control); alpha -amanitin for 1 h (amanitin); dexamethasone for 1 h (Dex); alpha -amanitin for 1 h followed by dexamethasone and additional incubation for 1 h (Dex + amanitin). Results are for a representative experiment. Results from duplicate experiments were similar.

alpha -Amanitin inhibits MMTV-driven transcription under our incubation conditions as illustrated by a representative experiment in Fig. 3. Specific transcription, or more properly RNA accumulation, was examined with an S1 protection assay. 3134 cells treated with dexamethasone for 1 h displayed a 7-8-fold increase in RNA detected relative to uninduced cells (Fig. 3; Control and Dex), comparable with previous determinations in the parental 904.13 cell line (44). Incubation of the cells with 50 µg/ml alpha -amanitin for 1 h before dexamethasone treatment resulted in approximately a 1.5-1.7-fold increase in transcript levels relative to control cells (Fig. 3; Amanitin + Dex). This represents a substantial 90-95% decrease in the steady state RNA level induced by dexamethasone after 1 h. A 50-70% decrease in the basal transcription of uninduced templates was also observed in cells treated with alpha -amanitin without dexamethasone (Fig. 3; Amanitin); however, the quantitation in this case is not as accurate because of the low RNA levels.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 3.   Incubation of 3134 cells with alpha -amanitin inhibits MMTV-driven RNA synthesis. Total RNA was extracted from treated or untreated 3134 cells, and MMTV LTR reporter-specific RNA assayed by S1 hybrid protection. The single-stranded probe spanned from +85 to -105. The signal from the protected hybrid was quantitated and normalized to the signal in untreated cells. The chart shows the fold-induction of cells treated as follows: untreated (control); alpha -amanitin for 1 h (amanitin); dexamethasone for 1 h (Dex); alpha -amanitin for 1 h followed by dexamethasone and additional incubation for 1 h (Dex + amanitin). Results are for a representative experiment. Results from duplicate experiments were similar.

Psoralen Accessibility and Unrestrained Supercoiling at the MMTV Promoter-- The rate of Me3-psoralen cross-linking to DNA depends on two parameters: the accessibility of the DNA and the level of unrestrained supercoiling in the DNA. Accessibility is dependent upon the extent of association of DNA with nucleosomes or other proteins that prevent Me3-psoralen binding (37). Psoralen accessibility of the MMTV promoter in this mouse cell was analyzed in four sets of cells: untreated (control) cells where the ha-v-ras gene was inactive; dexamethasone-treated cells that were transcriptionally active; cells treated with dexamethasone followed by alpha -amanitin, in which transcription elongation was allowed to proceed and then was blocked; and cells treated with alpha -amanitin followed by dexamethasone, in which the promoter was activated but transcription elongation was prevented. Each set of cells was treated with psoralen and exposed to increasing doses of 360-nm light. The DNA was irreversibly denatured as described under "Experimental Procedures," and the cross-linked and noncross-linked molecules were separated on a native agarose gel (Fig. 4A). The cross-links per kilobase (Xl/kb), calculated from the intensities of the cross-linked (Xl) and noncross-linked (non-Xl) SpeI fragments (Fig. 4A), showed a linear relationship as a function of light exposure for each set of cells (Fig. 4B). As shown in Fig. 4B, the cross-linking rates for the cell lines were linear to at least 12 kJ/m2. The molecular bases for the slight decrease in rate of binding in cells treated with dexamethasone (permeability or accessibility changes) was not investigated. In the experiments to determine the level of unrestrained negative superhelical energy, a dose of 6 kJ/m2 of 360-nm light was chosen because it is within the linear range of the cross-linking reaction.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 4.   Rate of psoralen cross-linking within the 1.8-megabase pair array. A, Southern analysis on DNA from dexamethasone-treated cells cross-linked for various times after exposure to psoralen. B, a plot of the Xl/kb as a function of light dose. Cells were treated with 360-nm light at an incident intensity of 1.2 kJ/m2/min. Samples were removed after various times and analyzed by Southern hybridization to determine the Xl/kb as described under "Experimental Procedures." open circle , untreated; , dexamethasone followed by alpha -amanitin treatment; down-triangle, dexamethasone; 224 , alpha -amanitin followed by dexamethasone treatment. Lines represent the linear regression, best fit to the data. Lines for the dexamethasone and the alpha -amanitin followed by dexamethasone treatment data are identical.

Unrestrained supercoiling was determined by comparing the Xl/kb at a constant dose of psoralen and light within the SpeI fragment before and after the chromosomal DNA was nicked by BrdUrd photolysis. In Fig. 5A the intensity of both the Xl and non-Xl species decreased at higher doses of nicking but proportionally the Xl band decreases faster (determined by PhosphorImager analysis). Thus, the rate of cross-linking (or Xl/kb versus dose) decreased at higher doses of 313-nm light indicating the presence of unrestrained supercoiling. The measurement of supercoiling is presented as RI/N as described previously (24, 26)). A value of RI/N = 1 indicates that no unrestrained supercoiling was detected, whereas an RI/N > 1 indicates the presence of negative supercoiling. All RI/N values in Fig. 5B represent the average from at least six independent determinations from three separate experiments. A moderately high level of unrestrained superhelical tension (RI/N = 1.55) was present in the promoter region in cells with an uninduced basal level of transcription of the MMTV promoter (Fig. 5B, Control). This level of supercoiling was lower than that observed in the Drosophila hsp70 or rRNA genes (24), but higher than that seen in a hygromycin gene in human cells (26). After dexamethasone treatment for 1 h, the overall level of negative superhelical energy dropped significantly (about 80%), to RI/N = 1.11 (Fig. 5B, Dex). The level of supercoiling in the MMTV promoter in cells treated with dexamethasone and then alpha -amanitin (for 1 h), RI/N = 1.43, was significantly higher than in the dexamethasone-treated cells (RI/N = 1.11). However, the level of supercoiling in these cells was 15-20% lower than in control (uninduced) cells with a basal level of expression (Fig. 5B, Dex + alpha -amanitin). Furthermore, cells treated with alpha -amanitin for 1 h and then dexamethasone for 1 h had a level of supercoiling of RI/N = 1.48, which is significantly higher than in the dexamethasone-treated cells (RI/N = 1.11) and about a 10-15% lower than in control cells (Fig. 5B, alpha -amanitin + Dex).


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 5.   Unrestrained supercoiling within the ras gene of the 1.8-megabase pair array. A, Southern analysis on intact and nicked chromosomal DNA from cells treated with alpha -amanitin and dexamethasone. Southern blot analysis was performed on DNA isolated from cells before and after exposure to 313-nm light. Cells were exposed to 0, 3, 5, 10, 15, and in some cases 18 and 20 min of 313-nm light, treated with Me3-psoralen, and then exposed to 0 or 6.0 kJ/m2 360-nm light. Xl indicates the cross-linked species and non-Xl indicates the non-cross-linked species of the SpeI fragment. B, bar graph showing the RI/N values for cells before and after 313-nm light exposure for untreated cells (Control), cells treated with dexamethasone alone (Dex), cells treated with dexamethasone followed by alpha -amanitin (Dex + alpha -amanitin), and cells treated with alpha -amanitin followed by dexamethasone (alpha -amanitin + Dex). RI/N values are average values calculated from multiple analyses of at least three separate experiments (n > 6). A solid line is drawn at the RI/N = 1 representing no unrestrained supercoiling. RI/N > 1 indicates the presence of unrestrained negative superhelical tension. The standard error of the mean values are shown as error bars.

Measurement of Topological Domains in 3134 Cells-- Different times of irradiation with 313-nm light that introduced nicks into the DNA were required to relax all supercoils in cells following the different treatments shown in Fig. 5B. In untreated cells, the relaxation of most supercoiling (>95%) within the SpeI fragment occurred after 5 min of nicking (Fig. 5B, Control), but relaxation required greater than 15-18 min of nicking in cells treated with dexamethasone and then alpha -amanitin or in cells treated with alpha -amanitin and then dexamethasone (Fig. 5B, Dex + alpha -amanitin, alpha -amanitin + Dex). The different doses of 313-nm light required for nicking suggest that the domain size in the tandem array may be different in the nontreated and treated mouse cells.

The psoralen assay for measurement of a topological domain size requires that the DNA contain unrestrained negative supercoils, and the assay measures the loss of superhelical tension as a function of the number of nicks introduced into DNA (37-39). The number of nicks introduced into the DNA by photolysis of BrdUrd-labeled DNA was measured by alkaline sucrose gradient sedimentation analysis. Alkaline sucrose gradient fractions were collected onto a nylon membrane and probed using Southern hybridization to determine the average molecular weight of the DNA containing the MMTV inserts within the tandem array. From this analysis, the number of strand breaks introduced into the MMTV tandem array as a function of the 313-nm light dose could be calculated.

The nicking rates were not significantly different statistically between the nontreated cells and cells treated with alpha -amanitin, dexamethasone, or any combination of the two. However a statistically significant 2-fold difference was observed between the cells that were treated with dexamethasone then alpha -amanitin and the cells that were treated with alpha -amanitin then dexamethasone (Fig. 6, insert, top and bottom lines). Treatment with dexamethasone followed by alpha -amanitin yielded the highest number of strand breaks, and this treatment may have resulted in the most open chromatin configuration. Treatment with alpha -amanitin would be expected to keep the chromosome more organized into nucleosomes and thus more protected from free radical attack during BrdUrd photolysis.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 6.   Estimation of domain size within the 1.8-megabase pair array. Insert, the single strand breaks per tandem array were determined by alkaline sucrose sedimentation analysis (see "Experimental Procedures") and are plotted against the time of exposure to 313-nm light. open circle , untreated; , alpha -amanitin followed by dexamethasone treatment; diamond  , dexamethasone followed by alpha -amanitin treatment. Alkaline sucrose gradient analysis generated the molecular weight of the single-stranded DNA fragments (Z). The number of bases/fragment = (Z) molecular weight of a single strand fragment/molecular weight per base (described under "Experimental Procedures"). Nicks/tandem array = (1.8 × 106 bp/tandem array)/(Y) × 2, where Y = the size of the single strand DNA (bp) (see Ref. 38). Lines represent the linear regression, best fit to the data. Main figure, experimental data are plotted as FR, the fraction of total supercoils remaining after various times of nicking verses the number of breaks introduced into the tandem array insert. FR values are calculated from the RI/N values determined at different nicking times FRx = (RI/N, 15 or 20 min - RI/N, X min) div  (RI/N, 15 or 20 min - RI/N, 0 min) (note that 15- or 20-min nicking was required to obtain the fully relaxed state), where RI/N, 0 min = 1. , untreated; diamond  , alpha -amanitin followed by dexamethasone; open circle  = dexamethasone followed by alpha -amanitin treatment. Theoretical curves were calculated using the formula FR = e-(x/m) using different values of m (domains/tandem array equivalent) and breaks/tandem array equivalent (x). The curves correspond to 20, 55, 110, 215, and 400 domains/tandem array, with the m = 20 curve decreasing to FR < 0.02 at about 100 breaks, and the m = 400 curve decreasing to FR = 0.2 at about 650 breaks.

To estimate the number of topological domains, it is assumed that the nicks are introduced in a Poisson distribution (1, 38, 39). Using the Poisson formula, theoretical curves are calculated to determine the best fit with the experimental data points (described in the legend to Fig. 6). In Fig. 6, three sets of experimental data are plotted against five theoretical curves each representing a different topological domain size. The theoretical curve that best fits the experimental data represents the domain size. The average number of topological domains/tandem array for untreated cells was 55/tandem array, or 32,000 bp/domain. For cells treated with alpha -amanitin and then dexamethasone, the number of domains was approximately 110/tandem array, or 16,000 bp/domain. For cells treated with dexamethasone and then alpha -amanitin approximately 215 domains/tandem array were present, with 8,000-9,000 bp/domain.

Treatment with dexamethasone or alpha -amanitin should not introduce major changes in chromosome structure that would influence the results obtained. The effects of dexamethasone have been extensively studied in the MMTV promoter (28, 45) and the TAT promoter (46). In both of these genes, dexamethasone is known to have very local effects on chromatin structure. Therefore, treatment with dexamethasone would not be expected to have global chromatin effects. In addition, no significant effect of dexamethasone treatment on the rate of nicking was observed when looking at the DNA size averaged over the entire chromosome (data not shown). In a previous analysis of a hyg gene in five random chromosomal locations in human cells, no unexpected differences in the rate of cross-linking were observed following alpha -amanitin treatment, other than those expected for a loss of supercoiling (26). Moreover, in two cell lines, no supercoiling was observed, and alpha -amanitin had no effect of cross-linking rates. In Drosophila experiments, using heat shock to induce the HSP70 genes, very little change was observed in the rRNA gene response to nicking or heat shock. In addition, differential changes were observed throughout locus 87A7, which were specific for the hsp70 transcription units, the flanking nontranscribed regions, and scs and scs' sequences (2). These total experiments argue against any global genome wide effects of induction of specific genes or alpha -amanitin treatment that would complicate the interpretation of the results.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this study the effect of transcriptional activation/elongation on unrestrained supercoiling and its relation to topological domain size was examined. Studies were performed on the MMTV promoter-driven ha-v-ras gene inserted in the chromosome of a mouse cell line. Analysis was completed using a psoralen-based assay for unrestrained negative supercoiling in combination with measuring the rate of loss of supercoils following the introduction of nicks into DNA by BrdUrd photolysis. Our results demonstrate that this MMTV promoter-driven ha-v-ras gene is maintained with a moderate level of unrestrained torsional tension in the uninduced state. Transcription elongation decreased negative supercoiling. This is the first example of a gene that becomes torsionally relaxed upon transcription. Transcriptional activation had little or no effect on supercoiling, and blocked elongating complexes also had little or no effect on negative unrestrained supercoiling. However, the activation of transcriptional complexes and the presence of elongating transcriptional complexes increased the number of topological domains within the MMTV promoter-gene region.

Unrestrained negative supercoiling in the tandem ha-v-ras genes was relaxed following the activation of transcription by addition of dexamethasone. This result is in contrast with certain models in which supercoiling has been thought to be a prerequisite for transcription and possibly a consequence of RNA polymerase movement during elongation (for example, see Ref. 4). In fact, transcription in the Drosophila hsp70 locus results in a slight increase in an already high level of unrestrained supercoiling (24). In the case of the ha-v-ras gene, the release of unrestrained supercoiling during active transcription may be due to the active recruitment or activation of topoisomerases within the locus.

Unrestrained supercoiling was maintained in cells treated with any combination of dexamethasone and alpha -amanitin; i.e. cells induced for transcription but in which active transcriptional elongation was inhibited. The level of unrestrained supercoiling in these cells (RI/N = 1.43, 1.48) was similar to that in uninduced cells (RI/N = 1.55). The slight decrease in supercoiling in cells treated with alpha -amanitin may be due to residual active transcription (90-95% of transcriptional elongation has been blocked, Fig. 3). Supercoiling was reestablished in cells treated with dexamethasone and then alpha -amanitin upon the inhibition of transcription elongation. The reestablishment of supercoiling occurred within the 1 h between alpha -amanitin treatment and the psoralen photobinding. If active transcriptional elongation is tightly coupled with the active topoisomerase(s) it is understandable that negative supercoiling could be rapidly relaxed. It is known that topoisomerase I is associated with regions of active transcription (47-49), and that it is also recruited to promoters by transcription factor IID (50, 51). That the inhibition of elongation leads to reestablishment of unrestrained supercoiling implies a mechanism exists for the regeneration, or loss of restraint, of supercoils. This mechanism does not appear to be dependent upon tracking by RNA polymerase. Furthermore, current evidence indicates that no loss of nucleosomes occurs from the LTR during activation (31, 52).

Changes in Topological Domain Organization Occur during Transcription of the ha-v-ras Gene-- The topological domain size changed dramatically upon transcription. In the mouse cell line 3134 there are approximately 200 tandem inserts containing the MMTV promoter, each insert is 9,000 bp in length, and the entire region consists of 1.8 × 106 bp. In cells in which the ha-v-ras gene was inactive approximately 55 topological domains existed, such that each domain was, on average, 32,000 bp in length. This is similar to the size found in the rDNA genes in humans fibrosarcoma cells (26). These domain boundaries may be defined by some structural attachment to a nuclear structure. Cells treated with alpha -amanitin and then dexamethasone had 110 topological domain boundaries resulting in 16,000 bp/domain. The change in the number of boundaries from the untreated to treated cells is about 50, which is 25% of the 200 inserts present. This is similar to the 15-20% increase in enzyme accessibility observed at various MMTV promoter sites upon dexamethasone treatment, which is likely due to transcriptional activation (28, 31) (for discussion see Ref. 27). These data are consistent with the hypothesis that transcriptional activation of the MMTV promoter creates a topological domain boundary in living mouse cells. (A topological domain size cannot be determined in cells induced for transcription because the domain assay required the presence of unrestrained supercoiling.)

Cells treated with dexamethasone and then alpha -amanitin had 9,000 bp/domain, a smaller domain size than in cells with simply activated transcription complexes (16,000 bp/domain). Under these conditions, the maximum number of transcription complexes are presumably formed before elongation is inhibited by alpha -amanitin. The number of domain boundaries created under these conditions of maximal gene induction is similar to the suggested number of MMTV promoters activated by dexamethasone treatment. These results strongly suggest that transcription complexes constitute transient (and mobile) topological domain boundaries and, thus, support the hypothesis that domain boundaries can be "functional" in nature (9).

These domain measurements represent approximate values, because it is uncertain if there are damaged sites from BruUrd photolysis that are alkali labile but do not represent breaks in vivo, as discussed previously (26). This may influence domain sizes by as much as 10-20%. Moreover, it is formally possible that not all torsional tension would be relaxed at a nick if DNA repair proteins bound to the site and prevented rotation about the nick. However, experiments are performed in phosphate-buffered saline buffer at 0-4 °C to prevent any such repair activity. In small bacterial chromosomes most supercoils appear to be lost, and only restrained supercoils remain following nicking in vivo (14, 22).

The observations that transcription can influence a topological domain size suggests several mechanisms for domain organization. In Fig. 7, top panel, the polymerase complex could establish a topological domain by simply preventing rotation of the DNA double helix. Polymerase complexes bound to the promoter sequence and polymerase complexes transcribing the gene can establish a topological domain. In this case rotation is prevented by restraints to rotational diffusion. Alternatively, in Fig. 7, bottom panel, the polymerase complex is recruited to a nuclear structure upon gene activation. Alternatively, the transcriptional machinery is localized at a nuclear structure and activation involves the association of the DNA with the localized, transcription complexes. In this case the DNA template feeds through the attached complex during elongation, as suggested for the tetA gene in E. coli (53). Attachment to a nuclear structure would clearly prevent rotation of the DNA and establish a topological domain.


View larger version (48K):
[in this window]
[in a new window]
 
Fig. 7.   Models for the generation of new domain boundaries. A, loading a large initiation complex, including RNA polymerase II, on the promoter provides a constraint to DNA rotation that effectively creates a new topological domain. B, receptor activation recruits the active promoter units to a nuclear structure that serves as an active center for transcription. These centers represent the domain boundaries.

In conclusion, our results establish that unrestrained supercoiling is present in the tandem array of MMTV inserts within a mouse cell. Active transcription decreases the level of unrestrained supercoiling within this gene. Remarkably, the topological domain size decreases when the MMTV promoter is activated by dexamethasone, and a further reduction is observed if an actively transcribed ha-v-ras gene is inhibited by alpha -amanitin. These results demonstrate that the transcriptional state of a gene can influence both the level of unrestrained supercoiling and the topological domain size. Although certain topological domains may be defined by the interaction of MARs with a nuclear structure, clearly some topological domains in eukaryotic cells appear to be defined, in some way, by active transcription complexes.

    ACKNOWLEDGEMENTS

We thank Norene O'Sullivan (NCI-Frederick) for expertise with pulsed field gel electrophoresis.

    FOOTNOTES

* This work was supported in part by Public Health Service Grant P01 ES05652 from the NIEHS, National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Dagger To whom correspondence should be addressed: Institute of Biosciences and Technology, Texas A&M University, 2121 W. Holcombe Blvd., Houston, TX 77030-3303. Tel.: 713-677-7664; Fax: 713-677-7689; E-mail: Rsinden@ibt.tamu.edu.

parallel Present address: Zeneca Laboratories, CTL H1.2 Alderley Park, Macclesfield, Cheshire SK10 4TJ, United Kingdom.

§ Present address: NINDS, NIH, Bldg. 36 4D-10, 9000 Rockville Pike, Bethesda, MD 20892.

** Present address: Depts. of Obstetrics and Gynecology and Molecular and Medical Pharmacology, 27-139 CHS UCLA School of Medicine, 10833 Le Conte Ave., Los Angeles, CA 90095-1740.

    ABBREVIATIONS

The abbreviations used are: MAR, matrix attachment region; SAR, scaffold attachment region; MMTV, mouse mammary tumor virus; Me2SO, dimethyl sulfoxide; CHEF, clamped homogeneous electric field; BPV, bovine papilloma virus; LTR, long terminal repeat; kb, kilobase pair(s); bp, base pair(s); Xl, cross-links; PIPES, 1,4-piperazinediethanesulfonic acid.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Sinden, R. R., and Pettijohn, D. E. (1981) Proc. Natl. Acad. Sci. U. S. A. 78, 224-228[Abstract/Free Full Text]
2. Jupe, E. R., Sinden, R. R., and Cartwright, I. L. (1995) Biochemistry 34, 2628-2633[CrossRef][Medline] [Order article via Infotrieve]
3. Jackson, D. A., Dickinson, P., and Cook, P. R. (1990) EMBO J. 9, 567-571[Medline] [Order article via Infotrieve]
4. Freeman, L. A., and Garrard, W. T. (1992) Crit. Rev. Eukaryotic Gene Expression 2, 165-209[Medline] [Order article via Infotrieve]
5. Sinden, R. R. (1994) DNA Structure and Function , Academic Press, San Diego
6. Cockerill, P. N., and Garrard, W. T. (1986) Cell 44, 273-282[CrossRef][Medline] [Order article via Infotrieve]
7. Gasser, S. M., and Laemmli, U. K. (1986) Cell 46, 521-530[CrossRef][Medline] [Order article via Infotrieve]
8. van Drunen, C. N., Sewalt, R. G. A. B., Oosterling, R. W., Weisbeek, P. J., Smeekens, S. C. M., and van Driel, R. (1999) Nucleic Acids Res. 27, 2924-2930[Abstract/Free Full Text]
9. Jackson, D. A., Dolle, A., Robertson, G., and Cook, P. R. (1992) Cell Biol. Int. Rep. 16, 687-696[Medline] [Order article via Infotrieve]
10. Chen, D., Bowater, R., Dorman, C. J., and Lilley, D. M. J. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 8784-8788[Abstract/Free Full Text]
11. Mirabella, A., and Gartenberg, M. R. (1997) EMBO J. 16, 523-533[CrossRef][Medline] [Order article via Infotrieve]
12. Koo, H. S., Claassen, L., Grossman, L., and Liu, L. F. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 1212-1216[Abstract/Free Full Text]
13. Sinden, R. R., Carlson, J. O., and Pettijohn, D. E. (1980) Cell 21, 773-783[CrossRef][Medline] [Order article via Infotrieve]
14. Pettijohn, D. E., and Pfenninger, O. (1980) Proc. Natl. Acad. Sci. U. S. A. 77, 1331-1335[Abstract/Free Full Text]
15. Broyles, S., and Pettijohn, D. E. (1986) J. Mol. Biol. 187, 47-60[CrossRef][Medline] [Order article via Infotrieve]
16. Drlica, K., and Rouviere-Yaniv, J. (1987) Microbiol. Rev. 51, 301-319[Free Full Text]
17. Drlica, K. (1990) Trends Genet. 6, 433-437[CrossRef][Medline] [Order article via Infotrieve]
18. Drlica, K. (1992) Mol. Microbiol. 6, 425-433[Medline] [Order article via Infotrieve]
19. Bliska, J. R., and Cozzarelli, N. R. (1987) J. Mol. Biol. 194, 205-218[CrossRef][Medline] [Order article via Infotrieve]
20. McClellan, J. A., Boublikova, P., Palecek, E., and Lilley, D. M. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 8373-8377[Abstract/Free Full Text]
21. Rahmouni, A. R., and Wells, R. D. (1989) Science 246, 358-363[Abstract/Free Full Text]
22. Zheng, G., Kochel, T., Hoepfner, R. W., Timmons, S. E., and Sinden, R. R. (1991) J. Mol. Biol. 221, 107-129[CrossRef][Medline] [Order article via Infotrieve]
23. Ljungman, M., and Hanawalt, P. C. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 6055-6059[Abstract/Free Full Text]
24. Jupe, E. R., Sinden, R. R., and Cartwright, I. L. (1993) EMBO J. 12, 1067-1075[Medline] [Order article via Infotrieve]
25. Ljungman, M., and Hanawalt, P. C. (1995) Nucleic Acids Res. 23, 1782-1789[Abstract/Free Full Text]
26. Kramer, P. R., and Sinden, R. R. (1997) Biochemistry 36, 3151-3158[CrossRef][Medline] [Order article via Infotrieve]
27. Hager, G. L., Archer, T. K., Fragoso, G., Bresnick, E. H., Tsukagoshi, Y., John, S., and Smith, C. L. (1993) Cold Spring Harbor Symp. Quant. Biol. 58, 63-71[Medline] [Order article via Infotrieve]
28. Richard-Foy, H., and Hager, G. L. (1987) EMBO J. 6, 2321-2328[Medline] [Order article via Infotrieve]
29. Archer, T. K., Cordingley, M. G., Wolford, R. G., and Hager, G. L. (1991) Mol. Cell. Biol. 11, 688-698[Abstract/Free Full Text]
30. Archer, T. K., LeFebvre, P., Wolford, R. G., and Hager, G. L. (1992) Science 255, 1573-1576[Abstract/Free Full Text]
31. Fragoso, G., John, S., Roberts, M. S., and Hager, G. L. (1995) Genes Dev. 9, 1933-1947[Abstract/Free Full Text]
32. Kaufman, E. R., and Davidson, R. L. (1978) Proc. Natl. Acad. Sci. U. S. A. 75, 4982-4986[Abstract/Free Full Text]
33. Pennie, W. D., Hager, G. L., and Smith, C. L. (1995) Mol. Cell. Biol. 15, 2125-2134[Abstract]
34. Ostrowski, M. C., Richard-Foy, H., Wolford, R. G., Berard, D. S., and Hager, G. L. (1983) Mol. Cell. Biol. 3, 2045-2057[Abstract/Free Full Text]
35. Workman, J. L., and Langmore, J. P. (1985) Biochemistry 24, 4731-4738[CrossRef][Medline] [Order article via Infotrieve]
36. Sinden, R. R., and Pettijohn, D. E. (1982) J. Mol. Biol. 162, 659-677[CrossRef][Medline] [Order article via Infotrieve]
37. Sinden, R. R., and Ussery, D. W. (1992) Methods Enzymol. 212, 319-335[Medline] [Order article via Infotrieve]
38. Kramer, P. R., Bat, O., and Sinden, R. R. (1999) Methods Enzymol. 304, 639-650[Medline] [Order article via Infotrieve]
39. Sinden, R. R., Bat, O., and Kramer, P. R. (1999) Methods Companion Methods Enzymol. 17, 112-124[CrossRef]
40. McMaster, G. K., and Carmichael, G. G. (1977) Proc. Natl. Acad. Sci. U. S. A. 74, 4835-4838[Abstract/Free Full Text]
41. Rupp, W. D., and Howard-Flanders, P. (1968) J. Mol. Biol. 31, 291-304[CrossRef][Medline] [Order article via Infotrieve]
42. Bresnick, E. H., Bustin, M., Marsaud, V., Richard-Foy, H., and Hager, G. L. (1992) Nucleic Acids Res. 20, 273-278[Abstract/Free Full Text]
43. Truss, M., Bartsch, J., Schelbert, A., Hache, R. J., and Beato, M. (1995) EMBO J. 14, 1737-1751[Medline] [Order article via Infotrieve]
44. Archer, T. K., Lee, H. L., Cordingley, M. G., Mymryk, J. S., Fragoso, G., Berard, D. S., and Hager, G. L. (1994) Mol. Endocrinol. 8, 568-576[Abstract]
45. Richard-Foy, H., Sistare, F. D., Riegel, A. T., Simons, S. S., Jr., and Hager, G. L. (1987) Mol. Endocrinol. 1, 659-665[Abstract]
46. Becker, P. B., Gloss, B., Schmid, W., Strahle, U., and Schutz, G. (1986) Nature 324, 686-688[CrossRef][Medline] [Order article via Infotrieve]
47. Weisbrod, S. T. (1982) Nucleic Acids Res. 10, 2017-2042[Abstract/Free Full Text]
48. Fleischmann, G., Pflugfelder, G., Steiner, E. K., Javaherian, K., Howard, G. C., Wang, J. C., and Elgin, S. C. R. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 6958-6962[Abstract/Free Full Text]
49. Gilmour, D. S., Pflugfelder, G., Wang, J. C., and Lis, J. T. (1986) Cell 44, 401-407[CrossRef][Medline] [Order article via Infotrieve]
50. Merino, A., Madden, K. R., Lane, W. S., Champoux, J. J., and Reinberg, D. (1993) Nature 365, 227-232[CrossRef][Medline] [Order article via Infotrieve]
51. Shykind, B. M., Kim, J., Stewart, L., Champoux, J. J., and Sharp, P. A. (1997) Genes Dev. 11, 397-407[Abstract/Free Full Text]
52. Fragoso, G., Pennie, W. D., John, S., and Hager, G. L. (1998) Mol. Cell. Biol. 18, 3633-3644[Abstract/Free Full Text]
53. Bowater, R. P., Chen, D., and Lilley, D. M. J. (1994) Biochemistry 33, 9266-9275[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea